



Incyte to Present at Lehman and BioCentury Conferences

March 24, 2005

WILMINGTON, Del.--(BUSINESS WIRE)--March 24, 2005--Incyte Corporation (Nasdaq:INCY) announced today it is scheduled to present at the following investor conferences:

- Lehman Brothers Global Healthcare Conference on Wednesday, March 30, 2005 at 2:30 p.m. (ET) in Miami
- BioCentury / Thomson Future Leaders in the Biotech Industry on Thursday, April 7, 2005 at 3:50 p.m. (ET) in New York City

John Keller, Ph.D., executive vice president and chief business officer of Incyte, will provide an overview of the company and discuss its most advanced drug discovery and development programs.

Audio webcasts of the presentations will be available at www.incyte.com under Investor Relations, Events and Webcasts.

About Incyte

Incyte Corporation is a Wilmington, Delaware based drug discovery and development company with a growing pipeline of oral compounds to treat HIV, inflammation, cancer and diabetes. The company's most advanced product candidate, Reverset(TM), is an oral, once-a-day therapy in Phase II clinical trials to treat patients with HIV infections. The company's lead internal compounds include INCB3284, a proprietary oral CCR2 antagonist that is entering Phase II development for a number of chronic inflammatory conditions and INCB7839, a proprietary, oral sheddase inhibitor that is entering Phase I development as a potential treatment for solid cancers. Incyte has several other early drug discovery programs.

Except for the historical information contained herein, the matters set forth in this press release, including the expected utility of the company's product candidates, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including developments affecting Incyte's research and development activities, the results of further research and development, and other risks detailed from time to time in Incyte's reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2004. Incyte disclaims any intent or obligation to update these forward-looking statements.

CONTACT: Incyte Corporation, Wilmington
Pamela M. Murphy, 302-498-6944

SOURCE: Incyte Corporation